Breakthrough cancer therapy developed at Penn receives 2nd FDA approval
The Food and Drug Administration on Tuesday approved a second indication for a revolutionary cancer therapy initially developed by researchers at the University of Pennsylvania's Abramson Cancer Center.
The FDA cleared Kymriah, a personalized cellular therapy marketed by Novartis, for use in patients with advanced non-Hodgkin's lymphoma. The FDA specifically approved Kymriah for the treatment of certain adult patients with relapsed or refractory diffuse large B-cell lymphoma.
The American Cancer …
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news